[go: up one dir, main page]

BRPI0509332A - implantes oculares biodegradáveis com caracterìsticas de liberação a longo prazo - Google Patents

implantes oculares biodegradáveis com caracterìsticas de liberação a longo prazo

Info

Publication number
BRPI0509332A
BRPI0509332A BRPI0509332-5A BRPI0509332A BRPI0509332A BR PI0509332 A BRPI0509332 A BR PI0509332A BR PI0509332 A BRPI0509332 A BR PI0509332A BR PI0509332 A BRPI0509332 A BR PI0509332A
Authority
BR
Brazil
Prior art keywords
long
release characteristics
implants
term release
biodegradable
Prior art date
Application number
BRPI0509332-5A
Other languages
English (en)
Inventor
Jane Guo Shiah
Qing Lin
Thierry Nivaggioli
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0509332(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0509332A publication Critical patent/BRPI0509332A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"IMPLANTES OCULARES BIODEGRADáVEIS COM CARACTERìSTICAS DE LIBERAçãO A LONGO PRAZO". Implantes biodegradáveis feitos sob medida e adequados para a implantação em uma região ou sítio ocular e métodos para o tratamento de condições oculares. Os implantes fornecem uma liberação prolongada de um agente ativo em uma quantidade terapeuticamente eficaz durante um período de tempo entre 30 dias e um ano, ou por mais tempo.
BRPI0509332-5A 2004-04-30 2005-04-14 implantes oculares biodegradáveis com caracterìsticas de liberação a longo prazo BRPI0509332A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/837,355 US8685435B2 (en) 2004-04-30 2004-04-30 Extended release biodegradable ocular implants
PCT/US2005/013143 WO2005110362A1 (en) 2004-04-30 2005-04-14 Biodegradable ocular implants with long-term release characteristics

Publications (1)

Publication Number Publication Date
BRPI0509332A true BRPI0509332A (pt) 2007-09-04

Family

ID=34966124

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509332-5A BRPI0509332A (pt) 2004-04-30 2005-04-14 implantes oculares biodegradáveis com caracterìsticas de liberação a longo prazo

Country Status (10)

Country Link
US (6) US8685435B2 (pt)
EP (2) EP1740153B2 (pt)
JP (4) JP5128274B2 (pt)
AR (1) AR048773A1 (pt)
AU (1) AU2005244195B2 (pt)
BR (1) BRPI0509332A (pt)
CA (1) CA2565329C (pt)
ES (1) ES2501942T3 (pt)
TW (1) TW200603838A (pt)
WO (1) WO2005110362A1 (pt)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ATE306951T1 (de) 2000-11-29 2005-11-15 Allergan Inc Verhinderung von transplantatabstossung im auge
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
EP1781264B1 (en) 2004-08-04 2013-07-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
AU2012216644B2 (en) * 2004-08-13 2014-04-10 Allergan, Inc. Ocular implant made by a double extrusion process
AU2016228285B2 (en) * 2004-08-13 2018-06-28 Allergan, Inc. Ocular implant made by a double extrusion process
AU2014201844B2 (en) * 2004-08-13 2016-06-16 Allergan, Inc Ocular implant made by a double extrusion process
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
EP1924292A2 (en) 2005-09-16 2008-05-28 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
PL1959925T3 (pl) * 2005-12-02 2017-05-31 (Osi) Eyetech, Inc. Mikrocząstki o kontrolowanym uwalnianiu
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
SI2010184T1 (sl) 2006-04-06 2013-05-31 Nupathe Inc. Implantati za zdravljenje stanj, povezanih z dopaminom
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
PT2051710E (pt) * 2006-08-07 2012-02-08 Bausch & Lomb Composições e métodos para tratar, reduzir, melhorar ou aliviar doenças oftálmicas do segmento posterior
WO2008060359A2 (en) * 2006-09-29 2008-05-22 Surmodics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
US20080103368A1 (en) * 2006-10-17 2008-05-01 Ari Craine Methods, devices, and computer program products for detecting syndromes
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
CA2681361A1 (en) * 2007-03-30 2008-10-09 Fovea Pharmaceuticals Sa Methods for treating neovascular ocular diseases
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US9125807B2 (en) * 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
AU2009221859B2 (en) 2008-03-05 2013-04-18 Alcon Inc. Methods and apparatus for treating glaucoma
US9610243B2 (en) 2008-04-18 2017-04-04 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
WO2009140246A2 (en) 2008-05-12 2009-11-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10588855B2 (en) 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
CN109045296A (zh) 2008-11-10 2018-12-21 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
US8551167B2 (en) 2008-11-20 2013-10-08 Insight Innovations, Llc Intraocular implant cell migration inhibition system
US20120232649A1 (en) 2008-11-20 2012-09-13 Insight Innovations, Llc Intraocular Lens Cell Migration Inhibition System
NZ592645A (en) 2008-11-20 2013-01-25 Insight Innovations Llc Biocompatible biodegradable intraocular implant system
US9943402B2 (en) 2008-11-20 2018-04-17 Insight Innovations, Llc Micropatterned intraocular implant
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
US8409606B2 (en) 2009-02-12 2013-04-02 Incept, Llc Drug delivery through hydrogel plugs
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
KR20110122846A (ko) 2009-02-24 2011-11-11 알렉시온 파마슈티칼스, 인코포레이티드 치료용 ｔｐｏ/ｅｐｏ 모방 펩티드를 포함하는 항체
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US20100278897A1 (en) * 2009-05-01 2010-11-04 Allergan, Inc. Intraocular bioactive agent delivery system with molecular partitioning system
AU2010249683B2 (en) 2009-05-18 2015-06-25 Glaukos Corporation Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US20100314162A1 (en) * 2009-06-10 2010-12-16 Ppg Industries Ohio, Inc. Microporous material derived from renewable polymers and articles prepared therefrom
KR20120105405A (ko) 2009-06-23 2012-09-25 알렉시온 파마슈티칼스, 인코포레이티드 보체 단백질에 결합하는 이중특이적 항체
EP2451375B1 (en) 2009-07-09 2018-10-03 Ivantis, Inc. Single operator device for delivering an ocular implant
CN102481404B (zh) 2009-07-09 2014-03-05 伊万提斯公司 眼部植入物
WO2011035013A2 (en) * 2009-09-17 2011-03-24 Surmodics Pharmaceuticals, Inc. Implant devices that differ by release profile and methods of making and using same
JP2013509448A (ja) * 2009-11-02 2013-03-14 ニューパス インコーポレーテッド パーキンソン病の治療方法
DK2498783T3 (en) 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
NZ629829A (en) 2010-04-30 2015-11-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
US8946170B2 (en) 2010-07-21 2015-02-03 Allergan, Inc. Sustained release siRNA for ocular drug delivery
PL2600930T3 (pl) 2010-08-05 2021-09-06 Forsight Vision4, Inc. Urządzenie wstrzykujące do dostarczania leku
ES2894940T3 (es) 2010-08-05 2022-02-16 Forsight Vision4 Inc Aparato para tratar un ojo
EP2600876B1 (en) 2010-08-05 2015-04-29 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
CN106214321B (zh) 2010-10-15 2018-08-28 科尼尔赛德生物医学公司 用于进入眼睛的装置
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2654715B1 (en) * 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
CA2826453A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
PL2717914T3 (pl) * 2011-06-10 2020-05-18 Ramscor, Inc. Formulacje o przedłużonym uwalnianiu do dostarczania białek do oka i sposoby ich wytwarzania
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
SI2755600T1 (sl) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Naprava za izmenjavo tekočine
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
WO2013119959A1 (en) 2012-02-09 2013-08-15 Novus International Inc. Heteroatom containing cyclic dimers
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
CA2878617A1 (en) 2012-07-12 2014-01-16 Houston Stephen Smith Matrix and layer compositions for protection of bioactives
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
KR20200065106A (ko) 2012-09-27 2020-06-08 알레간 인코포레이티드 단백질의 지속된 방출을 위한 생물분해성 약물 전달 시스템
US20150272877A1 (en) * 2012-10-26 2015-10-01 Allergan, Inc. Ketorolac-containing sustained release drug delivery systems
WO2014066653A1 (en) * 2012-10-26 2014-05-01 Allergan, Inc. Ketorolac-containing sustained release intraocular drug delivery systems
US20150290170A1 (en) * 2012-10-26 2015-10-15 Allergan, Inc. Ketorolac-containing sustained release drug delivery systems
EA034963B1 (ru) 2012-11-08 2020-04-13 Клиасайд Байомедикал, Инк. Способ лечения расстройства заднего сегмента глаза
US10617558B2 (en) 2012-11-28 2020-04-14 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
RU2641021C2 (ru) 2013-02-15 2018-01-17 Аллерган, Инк. Имплантат для пролонгированной доставки лекарственного средства
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
WO2014160958A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
CN105246529B (zh) 2013-05-03 2019-06-14 科尼尔赛德生物医学公司 用于眼部注射的设备和方法
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
KR102192596B1 (ko) 2013-08-07 2020-12-18 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
JP6543431B2 (ja) * 2013-10-10 2019-07-10 ユニバーシティー オブ ユタ リサーチ ファウンデーションＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｕｔａｈ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 眼内薬物送達デバイスおよび付随する方法
EP3351239B1 (en) 2013-10-31 2020-04-01 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
ES2869024T3 (es) * 2013-11-08 2021-10-22 Hollister Inc Catéteres oleófilos lubricados
EP3068403B2 (en) * 2013-11-15 2025-12-03 Allergan, Inc. Methods of treatment of ocular conditions with a sustained drug delivery implant
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CA2950187A1 (en) 2014-05-29 2015-12-03 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
KR102511477B1 (ko) * 2014-06-17 2023-03-16 클리어사이드 바이오메디컬, 인코포레이드 안구 후부 질환을 치료하기 위한 방법 및 디바이스
EP3157598A4 (en) 2014-06-20 2018-05-16 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
US10709547B2 (en) 2014-07-14 2020-07-14 Ivantis, Inc. Ocular implant delivery system and method
CA2955186C (en) 2014-07-15 2023-08-29 Forsight Vision4, Inc. Ocular implant delivery device and method
JP2017524034A (ja) 2014-08-08 2017-08-24 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法
KR102510540B1 (ko) 2014-10-03 2023-03-16 나노틱스 엘엘씨 가용성 생물분자의 생물학적 활성을 억제하기 위한 조성물 및 방법
WO2016077371A1 (en) 2014-11-10 2016-05-19 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
FR3028410A1 (fr) 2014-11-18 2016-05-20 Pierre Coulon Implant capsulaire multifonctionnel
EP3233056B1 (en) * 2014-12-15 2023-11-15 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of ocular disorders
EP3250588A1 (en) 2015-01-29 2017-12-06 Board of Trustees of Michigan State University Cryptic polypeptides and uses thereof
KR20180044839A (ko) 2015-03-06 2018-05-03 에어리 파마슈티컬즈, 인코포레이티드 임플란트 도포기 및 임플란트들을 투여하는 방법
US10627415B2 (en) 2015-03-12 2020-04-21 Board Of Trustees Of Michigan State University Compositions and methods for diagnosing, monitoring, and treating an autoimmune disease
EP3736287A1 (en) 2015-05-11 2020-11-11 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
JP2018515529A (ja) 2015-05-12 2018-06-14 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ ハイドロゲルからの薬物送達
AU2016297642A1 (en) 2015-07-22 2018-02-15 Incept, Llc Coated punctal plug
WO2017015604A1 (en) 2015-07-23 2017-01-26 Envisia Therapeutics, Inc. Intravitreal drug delivery systems for the treatment of ocular conditions
ES2962607T3 (es) 2015-08-14 2024-03-20 Alcon Inc Implante ocular con sensor de presión
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
GB201519811D0 (en) * 2015-11-10 2015-12-23 Univ Belfast Ocular compositions
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
KR20180084104A (ko) 2015-11-20 2018-07-24 포사이트 비젼4, 인크. 연장 방출 약물 전달 장치를 위한 다공성 구조물
WO2017106517A1 (en) 2015-12-15 2017-06-22 Ivantis, Inc. Ocular implant and delivery system
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
PT109154B (pt) * 2016-02-12 2019-11-05 Univ De Coimbra Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
JP7009384B2 (ja) 2016-04-05 2022-01-25 フォーサイト・ビジョン フォー・インコーポレーテッド 移植可能な眼薬送達デバイス
WO2017176762A1 (en) 2016-04-06 2017-10-12 Nanotics, Llc Particles comprising subparticles or nucleic acid scaffolds
EP3442479A1 (en) 2016-04-20 2019-02-20 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的插入深度的装置和方法
CA3036993A1 (en) 2016-09-02 2018-03-08 Aerie Pharmaceuticals, Inc. Implant applicators
WO2018175922A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
US11517476B2 (en) 2017-06-13 2022-12-06 Innfocus, Inc. Systems, methods, and apparatus for treatment of glaucoma
US20190062428A1 (en) 2017-06-19 2019-02-28 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
CN116271012A (zh) 2017-07-27 2023-06-23 瑞颂医药公司 高浓度抗c5抗体制剂
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
EP3678686A1 (en) 2017-09-08 2020-07-15 Bristol-Myers Squibb Company Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
BR112020008182A2 (pt) 2017-10-26 2020-10-27 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
KR20200093581A (ko) 2017-11-21 2020-08-05 포사이트 비젼4, 인크. 확장 가능한 포트 전달 시스템을 위한 유체 교환 기기 및 사용 방법
CA3207829A1 (en) 2018-02-22 2019-08-29 Alcon Inc. Ocular implant and delivery system
KR102495666B1 (ko) 2018-03-14 2023-02-06 서피스 온콜로지, 인크. Cd39에 결합하는 항체 및 이의 용도
CN120173101A (zh) 2018-03-22 2025-06-20 表面肿瘤学有限责任公司 抗il-27抗体及其用途
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
EP3781689A1 (en) 2018-04-19 2021-02-24 Checkmate Pharmaceuticals, Inc. Synthetic rig-i-like receptor agonists
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
JP2021525243A (ja) 2018-05-21 2021-09-24 コンパス セラピューティクス リミテッド ライアビリティ カンパニー Ｎｋ細胞による標的細胞の殺傷を増進するための組成物および方法
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
JP7538723B2 (ja) 2018-06-28 2024-08-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体の産生方法
WO2020018715A1 (en) 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
US12460004B2 (en) 2018-08-09 2025-11-04 Compass Therapeutics Llc Antibodies that bind CD277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020033923A1 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antigen binding agents that bind cd277 and uses thereof
WO2020092549A1 (en) 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
WO2020097054A1 (en) 2018-11-06 2020-05-14 Georgetown University Treating non-alcoholic steatohepatitis with cck inhibitors
CN119735694A (zh) 2018-11-13 2025-04-01 指南针制药有限责任公司 对抗检查点分子的多特异性结合构建体及其用途
SG11202105161YA (en) 2018-12-13 2021-06-29 Surface Oncology Inc Anti-il-27 antibodies and uses thereof
AU2019400857B2 (en) * 2018-12-21 2025-09-04 Re-Vana Therapeutics Ltd Coated ocular implants
SG11202107538VA (en) 2019-01-16 2021-08-30 Compass Therapeutics Llc Formulations of antibodies that bind human cd137 and uses thereof
EP3920899A2 (en) 2019-02-08 2021-12-15 The UAB Research Foundation Immunotherapy for the treatment and prevention of inflammatory bowel disease
AU2020283135A1 (en) * 2019-05-31 2022-01-06 Dose Medical Corporation Bioerodible polyester polymer implants and related methods of use
EP3990042A4 (en) 2019-06-27 2023-07-19 Layerbio, Inc. METHODS AND SYSTEMS FOR RELEASING EYE DEVICES
US12403291B2 (en) 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
MX2022003005A (es) 2019-09-16 2022-04-07 Surface Oncology Inc Composiciones y metodos de anticuerpos anti-cd39.
JP2022549854A (ja) 2019-09-25 2022-11-29 サーフィス オンコロジー インコーポレイテッド 抗ｉｌ－２７抗体及びその使用
US20220356234A1 (en) 2019-10-02 2022-11-10 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
WO2021081353A1 (en) 2019-10-23 2021-04-29 Checkmate Pharmaceuticals, Inc. Synthetic rig-i-like receptor agonists
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
US12275986B2 (en) 2020-01-06 2025-04-15 Duke University Biomarkers associated with checkpoint immune therapy and methods of using same
DK3861985T3 (da) 2020-02-06 2023-07-24 Ocular Therapeutix Inc Sammensætninger og fremgangsmåder til behandling af øjensygdomme
DK3884929T3 (da) 2020-03-25 2023-09-25 Ocular Therapeutix Inc Øjenimplantat indeholdende en tyrosinkinase-inhibitor
US12084509B2 (en) 2020-04-30 2024-09-10 Duke University Gene signatures for monitoring acute rejection and methods of using same
WO2021231720A1 (en) 2020-05-15 2021-11-18 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
CN116133663B (zh) 2020-07-21 2025-10-17 阿勒根公司 具有高前列腺酰胺负载量的眼内植入物
US11540940B2 (en) 2021-01-11 2023-01-03 Alcon Inc. Systems and methods for viscoelastic delivery
CA3215856A1 (en) 2021-05-07 2022-11-10 Alison O'neill Anti-il-27 antibodies and uses thereof
EP4348263A1 (en) 2021-05-28 2024-04-10 Alexion Pharmaceuticals, Inc. Methods for detecting cm-tma biomarkers
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
US20240026001A1 (en) 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
WO2023230116A1 (en) 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
CN119630398A (zh) 2022-08-16 2025-03-14 勃林格殷格翰国际有限公司 眼内用尼达尼布的药物制剂
CA3266977A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)
WO2024086306A1 (en) * 2022-10-19 2024-04-25 Vitakey Inc. Formulated food products
WO2024215649A1 (en) 2023-04-11 2024-10-17 Ocular Therapeutix, Inc. Ocular implant comprising axitinib polymorph iv
WO2024238421A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of biomarkers for the identification and treatment of complement-mediated disorders
WO2024238422A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US19098A (en) * 1858-01-12 Valve arrangement for steam-engines
DE430539C (de) 1922-04-21 1926-06-23 J G Farbenindustrie Akt Ges Verfahren zur Darstellung von AEthylenchlorid
US3986510A (en) 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US3985510A (en) * 1974-05-28 1976-10-12 Taylor Fred W Flash reactor unit
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
US5286763A (en) * 1983-03-22 1994-02-15 Massachusetts Institute Of Technology Bioerodible polymers for drug delivery in bone
JPS6050051U (ja) 1983-09-14 1985-04-08 日産車体株式会社 自動車のリヤスピ−カ取付け構造
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
JPH01500034A (ja) 1986-04-10 1989-01-12 ダラテック　プロプライエタリー　リミテッド ワクチンおよび植込剤
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
JP2702729B2 (ja) 1988-02-24 1998-01-26 エーザイ株式会社 徐放性埋込剤
JPH0216917A (ja) 1988-07-05 1990-01-19 Iseki & Co Ltd 脱穀装置の拡散装置
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
DE69105495T2 (de) 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
JPH08503450A (ja) 1992-08-06 1996-04-16 ワーナー−ランバート・コンパニー 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する２−チオインドール（セレノインドール）および関連ジスルフィド（セレニド）
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
EP0654256B1 (en) 1993-02-26 2000-08-02 Santen Pharmaceutical Co., Ltd. Biodegradable sclera plug
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
AU4611496A (en) 1995-02-28 1996-09-18 Innapharma, Inc. Elcatonin controlled release microsphere formulation for treatment of osteoporosis
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
JPH1170138A (ja) * 1997-07-02 1999-03-16 Santen Pharmaceut Co Ltd ポリ乳酸強膜プラグ
WO1999001156A1 (en) 1997-07-02 1999-01-14 Santen Pharmaceutical Co., Ltd. Polylactic acid scleral plugs
US6306426B1 (en) 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
EP1621219A3 (en) 2000-11-29 2006-03-22 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
ATE306951T1 (de) 2000-11-29 2005-11-15 Allergan Inc Verhinderung von transplantatabstossung im auge
ATE492293T1 (de) 2001-02-27 2011-01-15 Senju Pharma Co Arzneimittelfreisetzungssystem aus einem biologisch abbaubaren polymer
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
JP2004535431A (ja) * 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
US6488952B1 (en) * 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
JP4615862B2 (ja) * 2001-12-18 2011-01-19 ノボ・ノルデイスク・エー／エス 固形投与マイクロインプラント
US6541504B1 (en) 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
AU2003234439A1 (en) 2002-05-07 2003-11-11 Control Delivery Systems, Inc. Processes for forming a drug delivery device
CN1301692C (zh) 2002-09-18 2007-02-28 阿勒根公司 眼植入物导入的器械
WO2004043432A2 (en) * 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
US20040137059A1 (en) 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20050244500A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050244466A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods

Also Published As

Publication number Publication date
CA2565329C (en) 2014-10-07
US8974812B2 (en) 2015-03-10
AU2005244195B2 (en) 2011-06-30
JP2014133772A (ja) 2014-07-24
US20150209276A1 (en) 2015-07-30
ES2501942T3 (es) 2014-10-02
US20080241223A1 (en) 2008-10-02
JP5552102B2 (ja) 2014-07-16
US10154960B2 (en) 2018-12-18
JP2007535535A (ja) 2007-12-06
US20140035184A1 (en) 2014-02-06
JP5128274B2 (ja) 2013-01-23
TW200603838A (en) 2006-02-01
EP1740153B1 (en) 2014-06-25
WO2005110362A1 (en) 2005-11-24
AR048773A1 (es) 2006-05-24
US10874605B2 (en) 2020-12-29
CA2565329A1 (en) 2005-11-24
AU2005244195A1 (en) 2005-11-24
EP2777693A1 (en) 2014-09-17
US8895049B2 (en) 2014-11-25
US20190254964A1 (en) 2019-08-22
JP2012012408A (ja) 2012-01-19
US20050244467A1 (en) 2005-11-03
EP1740153A1 (en) 2007-01-10
JP5706020B2 (ja) 2015-04-22
EP1740153B2 (en) 2017-08-09
JP2012207028A (ja) 2012-10-25
US8685435B2 (en) 2014-04-01
US20140249123A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
BRPI0509332A (pt) implantes oculares biodegradáveis com caracterìsticas de liberação a longo prazo
MX2009005405A (es) Sistemas intraoculares de distribucion de farmaco.
BR0112361A (pt) Métodos para tratamento de condições oculares mediadas por inflamação
AR042790A1 (es) Uso de glucocorticoesteroides selectivos para la superficie ocular enel tratamiento del ojo seco
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
BRPI0406880A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de inibidores de anidrase carbÈnicos
UY28067A1 (es) Formulaciones de deposito de liberacion controlada
NZ597106A (en) Ophthalmic compositions comprising carnitine and methods for treating eyes
EP1605956A4 (en) ADMINISTRATION OF CAPSAICINOIDS
JP2007517543A5 (pt)
UY29152A1 (es) Composciones fungicidas
ATE402002T1 (de) Elektroverarbeitetes kollagen
NO20010694L (no) Cornealt pÕlegg
BR9915235A (pt) ácidos hialurÈnicos reticulados e usos médicos dos mesmos
BRPI0406879A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos
BRPI0519748A2 (pt) preparaÇço de curativo para resfriamento tàpico
AR022099A1 (es) Una composicion oftalmica de liberacion sostenida y un metodo para terapia ocular
TW200602031A (en) Antiinflammatory and pain-relieving agent for external, use
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
CN108853116A (zh) 具有释放活性成分能力的水性组成物及可重复使用的隐形眼镜产品
BRPI0612931B8 (pt) composição para aplicação na pele
IT1305306B1 (it) Uso della pirenoxina per la protezione dei tessuti corneali ininterventi di fotocheratectomia.
MY134562A (en) Methods and compositions to treat conditions associated with neovascularization
ES2183359T3 (es) Agente desinfectante de pezones por inmersion.
ATE359798T1 (de) Verwendungvon dextransulfat zur behandlung von ibmir

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.